| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8242875 | International Journal of Radiation Oncology*Biology*Physics | 2007 | 5 Pages |
Abstract
Conclusion: Pretreatment PSAV greater than 2.0 ng/mL/year is associated with reduced bDFS. However, PSAV is an independent predictor of bDFS only in high-risk patients. PSAV does not predict survival outcomes.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
David M.D., Scott M.D., Paul M.D., Mitchell M.D., James M.D., Tom M.D., Prostate Cohort Outcomes Initiative Prostate Cohort Outcomes Initiative,